|
|
Translational initiatives in thrombolytic therapy |
Melvin E. Klegerman() |
Department of Internal Medicine, Division of Cardiovascular Medicine, University of Texas Health Science Center at Houston (UTHealth), Houston, TX 77054, USA |
|
|
Abstract Once thrombi have formed as part of the pathology defining myocardial infarction, ischemic stroke, peripheral arterial disease, deep venous thrombosis or other embolic disorders, the only clinically meaningful thrombolytic agents available for reversing the thrombogenic process are various plasminogen activators. These agents are enzymes that reverse fibrin polymerization underlying the coagulation process by converting endogenous plasminogen to plasmin, which cleaves the fibrin network to form increasingly smaller protein fragments, a process known as fibrinolysis. For the most part, the major clinically used thrombolytics, tissue plasminogen activator, urokinase and streptokinase, as well as the experimentally investigated agent staphylokinase, are the products of recombinant DNA technology, which permits molecular optimization of clinical efficacy. In all cases of molecular optimization and targeting, however, the primary challenge of thrombolytic therapy remains hemorrhagic side effects, which are especially devastating when they occur intracerebrally. Currently, the best strategy to ameliorate this adverse effect is nanoparticulate encapsulation or complexation, and many strategies of this sort are being actively pursued. This review summarizes the variety of targeted and untargeted thrombolytic formulations that have been investigated in preclinical studies.
|
Keywords
thrombolytics
nanomedicine
plasminogen activators
|
Corresponding Author(s):
Melvin E. Klegerman
|
Just Accepted Date: 09 December 2016
Online First Date: 23 January 2017
Issue Date: 20 March 2017
|
|
1 |
Smalling RW. Molecular biology of plasminogen activators: what are the clinical implications of drug design? Am J Cardiol 1996; 78(12 12A): 2–7
https://doi.org/10.1016/S0002-9149(96)00736-9
pmid: 8990404
|
2 |
Nordt TK, Bode C. Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart 2003; 89(11): 1358–1362
https://doi.org/10.1136/heart.89.11.1358
pmid: 14594904
|
3 |
Van de Werf FJ. The ideal fibrinolytic: can drug design improve clinical results? Eur Heart J 1999; 20(20): 1452–1458
https://doi.org/10.1053/euhj.1999.1659
pmid: 10493843
|
4 |
Al-Shwafi KA, de Meester A, Pirenne B, Col JJ. Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction. Am Heart J 2003; 145(2): 217–225
https://doi.org/10.1067/mhj.2003.110
pmid: 12595837
|
5 |
Onundarson PT, Francis CW, Marder VJ. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential. J Lab Clin Med 1992; 120(1): 120–128
pmid: 1613318
|
6 |
Sakharov DV, Rijken DC. Superficial accumulation of plasminogen during plasma clot lysis. Circulation 1995; 92(7): 1883–1890
https://doi.org/10.1161/01.CIR.92.7.1883
pmid: 7671373
|
7 |
Novokhatny V, Taylor K, Zimmerman TP. Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis. J Thromb Haemost 2003; 1(5): 1034–1041
https://doi.org/10.1046/j.1538-7836.2003.00128.x
pmid: 12871374
|
8 |
El-Menyar AA, Altamimi OM, Gomaa MM, Dabdoob W, Abbas AA, Abdel Rahman MO, Bener A, Albinali HA. Clinical and biochemical predictors affect the choice and the short-term outcomes of different thrombolytic agents in acute myocardial infarction. Coron Artery Dis 2006; 17(5): 431–437
https://doi.org/10.1097/00019501-200608000-00006
pmid: 16845251
|
9 |
Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993; 24(3): 195–208
https://doi.org/10.1007/BF01833260
pmid: 8435475
|
10 |
Wessels MR. Regulation of virulence factor expression in group A streptococcus. Trends Microbiol 1999; 7(11): 428–430
https://doi.org/10.1016/S0966-842X(99)01604-2
pmid: 10542418
|
11 |
White HD, Van de Werf FJ. Thrombolysis for acute myocardial infarction. Circulation 1998; 97(16): 1632–1646
https://doi.org/10.1161/01.CIR.97.16.1632
pmid: 9593569
|
12 |
Malke H, Ferretti JJ. Streptokinase: cloning, expression, and excretion by Escherichia coli. Proc Natl Acad Sci USA 1984; 81(11): 3557–3561
https://doi.org/10.1073/pnas.81.11.3557
pmid: 6374659
|
13 |
Castellino FJ. Recent advances in the chemistry of the fibrinolytic system. Chem Rev 1981; 81(5): 431–446
https://doi.org/10.1021/cr00045a001
|
14 |
Jennings K. Antibodies to streptokinase. BMJ 1996; 312(7028): 393–394
https://doi.org/10.1136/bmj.312.7028.393
pmid: 8601101
|
15 |
Lee HS. How safe is the readministration of streptokinase? Drug Saf 1995; 13(2): 76–80
https://doi.org/10.2165/00002018-199513020-00002
pmid: 7576266
|
16 |
Wu XC, Ye R, Duan Y, Wong SL. Engineering of plasmin-resistant forms of streptokinase and their production in Bacillus subtilis: streptokinase with longer functional half-life. Appl Environ Microbiol 1998; 64(3): 824–829
pmid: 9501422
|
17 |
Banerjee A, Chisti Y, Banerjee UC. Streptokinase—a clinically useful thrombolytic agent. Biotechnol Adv 2004; 22(4): 287–307
https://doi.org/10.1016/j.biotechadv.2003.09.004
pmid: 14697452
|
18 |
Smith RA, Dupe RJ, English PD, Green J. Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. Nature 1981; 290(5806): 505–508
https://doi.org/10.1038/290505a0
pmid: 7219537
|
19 |
Shi GY, Chang BI, Su SW, Young KC, Wu DH, Chang LC, Tsai YS, Wu HL. Preparation of a novel streptokinase mutant with improved stability. Thromb Haemost 1998; 79(5): 992–997
pmid: 9609235
|
20 |
Pratap J, Rajamohan G, Dikshit KL. Characteristics of glycosylated streptokinase secreted from Pichia pastoris: enhanced resistance of SK to proteolysis by glycosylation. Appl Microbiol Biotechnol 2000; 53(4): 469–475
https://doi.org/10.1007/s002530051643
pmid: 10803905
|
21 |
Koide A, Suzuki S, Kobayashi S. Preparation of polyethylene glycol-modified streptokinase with disappearance of binding ability towards anti-serum and retention of activity. FEBS Lett 1982; 143(1): 73–76
https://doi.org/10.1016/0014-5793(82)80276-7
pmid: 6180928
|
22 |
Rajagopalan S, Gonias SL, Pizzo SV. A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function. J Clin Invest 1985; 75(2): 413–419
https://doi.org/10.1172/JCI111715
pmid: 3156148
|
23 |
Torrèns I, Ojalvo AG, Seralena A, Hayes O, de la Fuente J. A mutant streptokinase lacking the C-terminal 42 amino acids is less immunogenic. Immunol Lett 2000; 70(3): 213–218 PMID:10656677
https://doi.org/10.1016/S0165-2478(99)00151-0
|
24 |
MacFarlane RG, Pilling J. Fibrinolytic activity of normal urine. Nature 1947; 159(4049): 779
https://doi.org/10.1038/159779a0
pmid: 20241608
|
25 |
Williams JRB. The fibrinolytic activity of urine. Br J Exper Pathol 1951; 32:530–537
|
26 |
Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost 2005; 93(4): 627–630
pmid: 15841305
|
27 |
Bernik MB. Increased plasminogen activator (urokinase) in tissue culture after fibrin deposition. J Clin Invest 1973; 52(4): 823–834
https://doi.org/10.1172/JCI107246
pmid: 4266421
|
28 |
Nolan C, Hall LS, Barlow GH, Tribby II. Plasminogen activator from human embryonic kidney cell cultures. Evidence for a proactivator. Biochim Biophys Acta 1977; 496(2): 384–400
https://doi.org/10.1016/0304-4165(77)90321-X
pmid: 836903
|
29 |
Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost 1980; 43(2): 77–89
pmid: 6450468
|
30 |
Crippa MP. Urokinase-type plasminogen activator. Int J Biochem Cell Biol 2007; 39(4): 690–694
https://doi.org/10.1016/j.biocel.2006.10.008
pmid: 17118695
|
31 |
Rijken DC. Structure/function relationships of t-PA. In: Kluft C. Tissue-type Plasminogen Activator (t-PA): Physiological and Clincial Aspects. Boca Raton, FL: CRC Press, Inc., 1988:101–122
|
32 |
Testa JE, Quigley JP. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev 1990; 9(4): 353–367
https://doi.org/10.1007/BF00049524
pmid: 2129023
|
33 |
Franco P, Vocca I, Carriero MV, Alfano D, Cito L, Longanesi-Cattani I, Grieco P, Ossowski L, Stoppelli MP. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and αv β5 integrin. J Cell Sci 2006; 119(Pt 16): 3424–3434 PMID:16882693
https://doi.org/10.1242/jcs.03067
|
34 |
Irigoyen JP, Muñoz-Cánoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 1999; 56(1-2): 104–132
https://doi.org/10.1007/PL00000615
pmid: 11213252
|
35 |
Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003; 22(2-3): 205–222
https://doi.org/10.1023/A:1023099415940
pmid: 12784997
|
36 |
Alfano D, Iaccarino I, Stoppelli MP. Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels. J Biol Chem 2006; 281(26): 17758–17767
https://doi.org/10.1074/jbc.M601812200
pmid: 16632475
|
37 |
Collen D, Lijnen HR. Tissue-type plasminogen activator: a historical perspective and personal account. J Thromb Haemost 2004; 2(4): 541–546
https://doi.org/10.1111/j.1538-7933.2004.00645.x
pmid: 15102005
|
38 |
Bachmann F, Kruithof IE. Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost 1984; 10(1): 6–17
https://doi.org/10.1055/s-2007-1004403
pmid: 6422555
|
39 |
Verheijen JH, Caspers MP, Chang GT, de Munk GA, Pouwels PH, Enger-Valk BE. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J 1986; 5(13): 3525–3530
pmid: 3030730
|
40 |
Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257(6): 2912–2919
pmid: 7199524
|
41 |
Rånby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 1982; 704(3): 461–469
https://doi.org/10.1016/0167-4838(82)90068-1
pmid: 6214279
|
42 |
Bringmann P, Gruber D, Liese A, Toschi L, Krätzchmar J, Schleuning WD, Donner P. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995; 270(43): 25596–25603
https://doi.org/10.1074/jbc.270.43.25596
pmid: 7592732
|
43 |
Nesheim M, Fredenburgh JC, Larsen GR. The dissociation constants and stoichiometries of the interactions of Lys-plasminogen and chloromethyl ketone derivatives of tissue plasminogen activator and the variant delta FEIX with intact fibrin. J Biol Chem 1990; 265(35): 21541–21548
pmid: 2123871
|
44 |
Angles-Cano E. A spectrophotometric solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-tPA) for high-fibrin-affinity tissue plasminogen activators. Anal Biochem 1986; 153(2): 201–210
https://doi.org/10.1016/0003-2697(86)90082-5
pmid: 3085533
|
45 |
Tsurupa G, Medved L. Fibrinogen alpha C domains contain cryptic plasminogen and tPA binding sites. Ann N Y Acad Sci 2001; 936(1): 328–330
https://doi.org/10.1111/j.1749-6632.2001.tb03518.x
pmid: 11460488
|
46 |
Klegerman ME, Zou Y, McPherson DD. Fibrin targeting of echogenic liposomes with inactivated tissue plasminogen activator. J Liposome Res 2008; 18(2): 95–112
https://doi.org/10.1080/08982100802118482
pmid: 18569446
|
47 |
Tiukinhoy-Laing SD, Buchanan K, Parikh D, Huang S, MacDonald RC, McPherson DD, Klegerman ME. Fibrin targeting of tissue plasminogen activator-loaded echogenic liposomes. J Drug Target 2007; 15(2): 109–114
https://doi.org/10.1080/10611860601140673
pmid: 17365281
|
48 |
Schielen WJ, Adams HP, van Leuven K, Voskuilen M, Tesser GI, Nieuwenhuizen W. The sequence γ-(312-324) is a fibrin-specific epitope. Blood 1991; 77(10): 2169–2173
pmid: 1709373
|
49 |
Schielen WJ, Adams HP, Voskuilen M, Tesser GI, Nieuwenhuizen W. The sequence A α-(154-159) of fibrinogen is capable of accelerating the t-PA catalysed activation of plasminogen. Blood Coagul Fibrinolysis 1991; 2(3): 465–470
https://doi.org/10.1097/00001721-199106000-00010
pmid: 1932532
|
50 |
Schielen WJ, Voskuilen M, Tesser GI, Nieuwenhuizen W. The sequence A α-(148-160) in fibrin, but not in fibrinogen, is accessible to monoclonal antibodies. Proc Natl Acad Sci USA 1989; 86(22): 8951–8954
https://doi.org/10.1073/pnas.86.22.8951
pmid: 2813432
|
51 |
Nieuwenhuizen W. Fibrin-mediated plasminogen activation. Ann N Y Acad Sci 2001; 936(1): 237–246
https://doi.org/10.1111/j.1749-6632.2001.tb03512.x
pmid: 11460481
|
52 |
Yakovlev S, Makogonenko E, Kurochkina N, Nieuwenhuizen W, Ingham K, Medved L. Conversion of fibrinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites. Biochemistry 2000; 39(51): 15730–15741
https://doi.org/10.1021/bi001847a
pmid: 11123898
|
53 |
Grailhe P, Nieuwenhuizen W, Anglés-Cano E. Study of tissue-type plasminogen activator binding sites on fibrin using distinct fragments of fibrinogen. Eur J Biochem 1994; 219(3): 961–967
https://doi.org/10.1111/j.1432-1033.1994.tb18578.x
pmid: 8112348
|
54 |
Yonekawa O, Voskuilen M, Nieuwenhuizen W. Localization in the fibrinogen gamma-chain of a new site that is involved in the acceleration of the tissue-type plasminogen activator-catalysed activation of plasminogen. Biochem J 1992; 283(Pt 1): 187–191
https://doi.org/10.1042/bj2830187
pmid: 1567367
|
55 |
Hurtado M, Lozano JJ, Castellanos E, López-Fernández LA, Harshman K, Martínez-A C, Ortiz AR, Thomson TM, Paciucci R. Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells. Gut 2007; 56(9): 1266–1274
https://doi.org/10.1136/gut.2006.097188
pmid: 17452424
|
56 |
Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983; 301(5897): 214–221
https://doi.org/10.1038/301214a0
pmid: 6337343
|
57 |
Wallén P, Pohl G, Bergsdorf N, Rånby M, Ny T, Jörnvall H. Purification and characterization of a melanoma cell plasminogen activator. Eur J Biochem 1983; 132(3): 681–686
https://doi.org/10.1111/j.1432-1033.1983.tb07418.x
pmid: 6682760
|
58 |
Strassburger W, Wollmer A, Pitts JE, Glover ID, Tickle IJ, Blundell TL, Steffens GJ, Günzler WA, Otting F, Flohé L. Adaptation of plasminogen activator sequences to known protease structures. FEBS Lett 1983; 157(2): 219–223
https://doi.org/10.1016/0014-5793(83)80551-1
pmid: 6345197
|
59 |
Kaneko M, Sakata Y, Matsuda M, Mimuro J. Interactions between the finger and kringle-2 domains of tissue-type plasminogen activator and plasminogen activator inhibitor-1. J Biochem 1992; 111(2): 244–248
pmid: 1314812
|
60 |
Ibarra CA, Blouse GE, Christian TD, Shore JD. The contribution of the exosite residues of plasminogen activator inhibitor-1 to proteinase inhibition. J Biol Chem 2004; 279(5): 3643–3650
https://doi.org/10.1074/jbc.M310601200
pmid: 14594804
|
61 |
Madison EL, Goldsmith EJ, Gerard RD, Gething MJ, Sambrook JF. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature 1989; 339(6227): 721–724
https://doi.org/10.1038/339721a0
pmid: 2500599
|
62 |
Rijken DC, Emeis JJ, Gerwig GJ. On the composition and function of the carbohydrate moiety of tissue-type plasminogen activator from human melanoma cells. Thromb Haemost 1985; 54(4): 788–791
pmid: 3937276
|
63 |
Pohl G, Källström M, Bergsdorf N, Wallén P, Jörnvall H. Tissue plasminogen activator: peptide analyses confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences. Biochemistry 1984; 23(16): 3701–3707
https://doi.org/10.1021/bi00311a020
pmid: 6433976
|
64 |
Emeis JJ, van den Hoogen CM, Jense D. Hepatic clearance of tissue-type plasminogen activator in rats. Thromb Haemost 1985; 54(3): 661–664
pmid: 3937264
|
65 |
Fuchs HE, Berger H Jr, Pizzo SV. Catabolism of human tissue plasminogen activator in mice. Blood 1985; 65(3): 539–544
pmid: 4038613
|
66 |
Little SP, Bang NU, Harms CS, Marks CA, Mattler LE. Functional properties of carbohydrate-depleted tissue plasminogen activator. Biochemistry 1984; 23(25): 6191–6195
https://doi.org/10.1021/bi00320a046
pmid: 6441597
|
67 |
Rånby M, Bergsdorf N, Pohl G, Wallén P. Isolation of two variants of native one-chain tissue plasminogen activator. FEBS Lett 1982; 146(2): 289–292
https://doi.org/10.1016/0014-5793(82)80936-8
pmid: 6890472
|
68 |
Zamarron C, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator. J Biol Chem 1984; 259(4): 2080–2083
pmid: 6538196
|
69 |
Collen D, Stassen JM, Marafino BJ Jr, Builder S, De Cock F, Ogez J, Tajiri D, Pennica D, Bennett WF, Salwa J, . Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. J Pharmacol Exp Ther 1984; 231(1): 146–152
pmid: 6541693
|
70 |
TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. N Engl J Med 1985; 312(14): 932–936
https://doi.org/10.1056/NEJM198504043121437
pmid: 4038784
|
71 |
The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329(10): 673–682 PMID:8204123
https://doi.org/10.1056/NEJM199309023291001
|
72 |
The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329(22): 1615–1622
https://doi.org/10.1056/NEJM199311253292204
pmid: 8232430
|
73 |
Cannon CP. Advances in the medical management of acute coronary syndromes. J Thromb Thrombolysis 1999; 7(2): 171–189
https://doi.org/10.1023/A:1008841721975
pmid: 10364769
|
74 |
Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM; Cleveland Clinic Health System Stroke Quality Improvement Team. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004; 61(3): 346–350 PMID:15023810
https://doi.org/10.1001/archneur.61.3.346
|
75 |
Smith WS. Technology Insight: recanalization with drugs and devices during acute ischemic stroke. Nat Clin Pract Neurol 2007; 3(1): 45–53
https://doi.org/10.1038/ncpneuro0372
pmid: 17205074
|
76 |
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333(24): 1581–1587 PMID:7477192
https://doi.org/10.1056/NEJM199512143332401
|
77 |
Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001; 56(8): 1015–1020
https://doi.org/10.1212/WNL.56.8.1015
pmid: 11320171
|
78 |
Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, Alwell K, Gebel J, Szaflarski J, Pancioli A, Jauch E, Moomaw C, Shukla R, Broderick JP; Neuroscience Institute. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke 2004; 35(2): e27–e29 PMID:14739423
https://doi.org/10.1161/01.STR.0000109767.11426.17
|
79 |
Kwan J, Hand P, Sandercock P. A systematic review of barriers to delivery of thrombolysis for acute stroke. Age Ageing 2004; 33(2): 116–121
https://doi.org/10.1093/ageing/afh064
pmid: 14960425
|
80 |
Brown DL, Barsan WG, Lisabeth LD, Gallery ME, Morgenstern LB. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med 2005; 46(1): 56–60
https://doi.org/10.1016/j.annemergmed.2004.12.025
pmid: 15988427
|
81 |
Liang BA, Lew R, Zivin JA. Review of tissue plasminogen activator, ischemic stroke, and potential legal issues. Arch Neurol 2008; 65(11): 1429–1433
https://doi.org/10.1001/archneur.65.11.1429
pmid: 19001160
|
82 |
Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 2003; 34(12): 2847–2850
https://doi.org/10.1161/01.STR.0000101752.23813.C3
pmid: 14605319
|
83 |
Berkowitz SD, Granger CB, Pieper KS, Lee KL, Gore JM, Simoons M, Armstrong PW, Topol EJ, Califf RM; The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. Circulation 1997; 95(11): 2508–2516 PMID:9184581
https://doi.org/10.1161/01.CIR.95.11.2508
|
84 |
Califf RM, Topol EJ, George BS, Boswick JM, Abbottsmith C, Sigmon KN, Candela R, Masek R, Kereiakes D, O’Neill WW, Stack RS, Stump D. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. Am J Med 1988; 85(3): 353–359
https://doi.org/10.1016/0002-9343(88)90586-4
pmid: 3137818
|
85 |
Yadav YR, Mukerji G, Shenoy R, Basoor A, Jain G, Nelson A. Endoscopic management of hypertensive intraventricular haemorrhage with obstructive hydrocephalus. BMC Neurol 2007; 7(1): 1
https://doi.org/10.1186/1471-2377-7-1
pmid: 17204141
|
86 |
Wu H, Zhang Z, Hu X, Zhao R, Song Y, Ban X, Qi J, Wang J. Dynamic changes of inflammatory markers in brain after hemorrhagic stroke in humans: a postmortem study. Brain Res 2010; 1342: 111–117
https://doi.org/10.1016/j.brainres.2010.04.033
pmid: 20420814
|
87 |
IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004; 35(4): 904–911
https://doi.org/10.1161/01.STR.0000121641.77121.98
pmid: 15017018
|
88 |
Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, Montaner J, Saqqur M, Demchuk AM, Moyé LA, Hill MD, Wojner AW; CLOTBUST Investigators. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004; 351(21): 2170–2178 PMID:15548777
https://doi.org/10.1056/NEJMoa041175
|
89 |
Donnan GA, Davis SM, Parsons MW, Ma H, Dewey HM, Howells DW. How to make better use of thrombolytic therapy in acute ischemic stroke. Nat Rev Neurol 2011; 7(7): 400–409
https://doi.org/10.1038/nrneurol.2011.89
pmid: 21670766
|
90 |
Martin U, Kohnert U, Stern A, Popp F, Fischer S. Comparison of the recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator with alteplase, reteplase and streptokinase in a canine model of coronary artery thrombolysis. Thromb Haemost 1996; 76(6): 1096–1101
pmid: 8972037
|
91 |
Kohnert U, Hellerbrand K, Martin U, Stern A, Popp F, Fischer S. The recombinant Escherichia coli-derived protease-domain of tissue-type plasminogen activator is a potent and fibrin specific fibrinolytic agent. Fibrinolysis 1996; 10(2): 93–102
https://doi.org/10.1016/S0268-9499(96)80084-1
|
92 |
Dundar Y, Hill R, Dickson R, Walley T. Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review. QJM 2003; 96(2): 103–113
https://doi.org/10.1093/qjmed/hcg016
pmid: 12589008
|
93 |
Llevadot J, Giugliano RP, Antman EM. Bolus fibrinolytic therapy in acute myocardial infarction. JAMA 2001; 286(4): 442–449
https://doi.org/10.1001/jama.286.4.442
pmid: 11466123
|
94 |
Shaw GJ, Meunier JM, Lindsell CJ, Holland CK. Tissue plasminogen activator concentration dependence of 120 kHz ultrasound-enhanced thrombolysis. Ultrasound Med Biol 2008; 34(11): 1783–1792
https://doi.org/10.1016/j.ultrasmedbio.2008.03.020
pmid: 18468773
|
95 |
Behnke D, Gerlach D. Cloning and expression in Escherichia coli, Bacillus subtilis, and Streptococcus sanguis of a gene for staphylokinase—a bacterial plasminogen activator. Mol Gen Genet 1987; 210(3): 528–534
https://doi.org/10.1007/BF00327208
pmid: 3123893
|
96 |
Collen D, Zhao ZA, Holvoet P, Marynen P. Primary structure and gene structure of staphylokinase. Fibrinolysis 1992; 6(4): 226–231
https://doi.org/10.1016/0268-9499(92)90075-S
|
97 |
Laroche Y, Heymans S, Capaert S, De Cock F, Demarsin E, Collen D. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood 2000; 96(4): 1425–1432
pmid: 10942387
|
98 |
Armstrong PW, Burton JR, Palisaitis D, Thompson CR, Van de Werf F, Rose B, Collen D, Teo KK. Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS). Am Heart J 2000; 139(5): 820–823
https://doi.org/10.1016/S0002-8703(00)90013-9
pmid: 10783215
|
99 |
Ntimenou V, Mourtas S, Christodoulakis EV, Tsilimbaris M, Antimisiaris SG. Stability of protein-encapsulating DRV liposomes after freeze-drying: A study with BSA and t-PA. J Liposome Res 2006; 16(4): 403–416
https://doi.org/10.1080/08982100600993003
pmid: 17162581
|
100 |
Soeda S, Kakiki M, Shimeno H, Nagamatsu A. Some properties of tissue-type plasminogen activator reconstituted onto phospholipid and/or glycolipid vesicles. Biochem Biophys Res Commun 1987; 146(1): 94–100
https://doi.org/10.1016/0006-291X(87)90695-4
pmid: 3111472
|
101 |
Heeremans JL, Gerritsen HR, Meusen SP, Mijnheer FW, Gangaram Panday RS, Prevost R, Kluft C, Crommelin DJ. The preparation of tissue-type Plasminogen Activator (t-PA) containing liposomes: entrapment efficiency and ultracentrifugation damage. J Drug Target 1995; 3(4): 301–310
https://doi.org/10.3109/10611869509015959
pmid: 8821004
|
102 |
Heeremans JL, Prevost R, Bekkers ME, Los P, Emeis JJ, Kluft C, Crommelin DJ. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA. Thromb Haemost 1995; 73(3): 488–494
pmid: 7667833
|
103 |
Kim JY, Kim JK, Park JS, Byun Y, Kim CK. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials 2009; 30(29): 5751–5756
https://doi.org/10.1016/j.biomaterials.2009.07.021
pmid: 19656559
|
104 |
Han SB, Baek SH, Park JS, Yang HK, Kim JY, Kim CK, Hwang JM. Effect of subconjunctivally injected liposome-encapsulated tissue plasminogen activator on the absorption rate of subconjunctival hemorrhages in rabbits. Cornea 2011; 30(12): 1455–1460
https://doi.org/10.1097/ICO.0b013e3182120fb9
pmid: 21955629
|
105 |
Absar S, Choi S, Ahsan F, Cobos E, Yang VC, Kwon YM. Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis. Thromb Res 2013; 131(3): e91–e99
https://doi.org/10.1016/j.thromres.2012.11.030
pmid: 23269380
|
106 |
Absar S, Choi S, Yang VC, Kwon YM. Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis. J Control Release 2012; 157(1): 46–54
https://doi.org/10.1016/j.jconrel.2011.09.060
pmid: 21930168
|
107 |
Holt B, Gupta AS. Streptokinase loading in liposomes for vascular targeted nanomedicine applications: encapsulation efficiency and effects of processing. J Biomater Appl 2012; 26(5): 509–527
https://doi.org/10.1177/0885328210374778
pmid: 20659961
|
108 |
Kim IS, Choi HG, Choi HS, Kim BK, Kim CK. Prolonged systemic delivery of streptokinase using liposome. Arch Pharm Res 1998; 21(3): 248–252
https://doi.org/10.1007/BF02975283
pmid: 9875439
|
109 |
Erdoğan S, Ozer AY, Volkan B, Caner B, Bilgili H. Thrombus localization by using streptokinase containing vesicular systems. Drug Deliv 2006; 13(4): 303–309
https://doi.org/10.1080/10717540600559544
pmid: 16766472
|
110 |
Perkins WR, Vaughan DE, Plavin SR, Daley WL, Rauch J, Lee L, Janoff AS. Streptokinase entrapment in interdigitation-fusion liposomes improves thrombolysis in an experimental rabbit model. Thromb Haemost 1997; 77(6): 1174–1178
pmid: 9241753
|
111 |
Nguyen PD, O’Rear EA, Johnson AE, Patterson E, Whitsett TL, Bhakta R. Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase. Circ Res 1990; 66(3): 875–878
https://doi.org/10.1161/01.RES.66.3.875
pmid: 2306811
|
112 |
Wang X, Inapagolla R, Kannan S, Lieh-Lai M, Kannan RM. Synthesis, characterization, and in vitro activity of dendrimer-streptokinase conjugates. Bioconjug Chem 2007; 18(3): 791–799
https://doi.org/10.1021/bc060322d
pmid: 17429940
|
113 |
Leach JK, Patterson E, O’Rear EA. Distributed intraclot thrombolysis: mechanism of accelerated thrombolysis with encapsulated plasminogen activators. J Thromb Haemost 2004; 2(9): 1548–1555
https://doi.org/10.1111/j.1538-7836.2004.00884.x
pmid: 15333029
|
114 |
Erdoğan S, Ozer AY, Bilgili H. In vivo behaviour of vesicular urokinase. Int J Pharm 2005; 295(1-2): 1–6
https://doi.org/10.1016/j.ijpharm.2005.01.021
pmid: 15847986
|
115 |
Datta S, Coussios CC, Ammi AY, Mast TD, de Courten-Myers GM, Holland CK. Ultrasound-enhanced thrombolysis using Definity as a cavitation nucleation agent. Ultrasound Med Biol 2008; 34(9): 1421–1433
https://doi.org/10.1016/j.ultrasmedbio.2008.01.016
pmid: 18378380
|
116 |
Alexandrov AV, Mikulik R, Ribo M, Sharma VK, Lao AY, Tsivgoulis G, Sugg RM, Barreto A, Sierzenski P, Malkoff MD, Grotta JC. A pilot randomized clinical safety study of sonothrombolysis augmentation with ultrasound-activated perflutren-lipid microspheres for acute ischemic stroke. Stroke 2008; 39(5): 1464–1469
https://doi.org/10.1161/STROKEAHA.107.505727
pmid: 18356546
|
117 |
Molina CA, Ribo M, Rubiera M, Montaner J, Santamarina E, Delgado-Mederos R, Arenillas JF, Huertas R, Purroy F, Delgado P, Alvarez-Sabín J. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke 2006; 37(2): 425–429
https://doi.org/10.1161/01.STR.0000199064.94588.39
pmid: 16373632
|
118 |
Daffertshofer M, Gass A, Ringleb P, Sitzer M, Sliwka U, Els T, Sedlaczek O, Koroshetz WJ, Hennerici MG. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke 2005; 36(7): 1441–1446
https://doi.org/10.1161/01.STR.0000170707.86793.1a
pmid: 15947262
|
119 |
Ren ST, Zhang H, Wang YW, Jing BB, Li YX, Liao YR, Kang XN, Zang WJ, Wang B. The preparation of a new self-made microbubble-loading urokinase and its thrombolysis combined with low-frequency ultrasound in vitro. Ultrasound Med Biol 2011; 37(11): 1828–1837
https://doi.org/10.1016/j.ultrasmedbio.2011.06.018
pmid: 21925787
|
120 |
Francis CW. Ultrasound-enhanced thrombolysis. Echocardiography 2001; 18(3): 239–246
https://doi.org/10.1046/j.1540-8175.2001.00239.x
pmid: 11322907
|
121 |
Uesugi Y, Kawata H, Jo J, Saito Y, Tabata Y. An ultrasound-responsive nano delivery system of tissue-type plasminogen activator for thrombolytic therapy. J Control Release 2010; 147(2): 269–277
https://doi.org/10.1016/j.jconrel.2010.07.127
pmid: 20696194
|
122 |
Kawata H, Uesugi Y, Soeda T, Takemoto Y, Sung JH, Umaki K, Kato K, Ogiwara K, Nogami K, Ishigami K, Horii M, Uemura S, Shima M, Tabata Y, Saito Y. A new drug delivery system for intravenous coronary thrombolysis with thrombus targeting and stealth activity recoverable by ultrasound. J Am Coll Cardiol 2012; 60(24): 2550–2557
https://doi.org/10.1016/j.jacc.2012.08.1008
pmid: 23158532
|
123 |
Gupta AS, Huang G, Lestini BJ, Sagnella S, Kottke-Marchant K, Marchant RE. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system. Thromb Haemost 2005; 93(1): 106–114
pmid: 15630499
|
124 |
Huang G, Zhou Z, Srinivasan R, Penn MS, Kottke-Marchant K, Marchant RE, Gupta AS. Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets. Biomaterials 2008; 29(11): 1676–1685
https://doi.org/10.1016/j.biomaterials.2007.12.015
pmid: 18192005
|
125 |
Vaidya B, Nayak MK, Dash D, Agrawal GP, Vyas SP. Development and characterization of site specific target sensitive liposomes for the delivery of thrombolytic agents. Int J Pharm 2011; 403(1-2): 254–261
https://doi.org/10.1016/j.ijpharm.2010.10.028
pmid: 20971175
|
126 |
Wang SS, Chou NK, Chung TW. The t-PA-encapsulated PLGA nanoparticles shelled with CS or CS-GRGD alter both permeation through and dissolving patterns of blood clots compared with t-PA solution: an in vitro thrombolysis study. J Biomed Mater Res A 2009; 91(3): 753–761
https://doi.org/10.1002/jbm.a.32234
pmid: 19051299
|
127 |
Mu Y, Li L, Ayoufu G. Experimental study of the preparation of targeted microbubble contrast agents carrying urokinase and RGDS. Ultrasonics 2009; 49(8): 676–681
https://doi.org/10.1016/j.ultras.2009.05.003
pmid: 19559452
|
128 |
Hua X, Liu P, Gao YH, Tan KB, Zhou LN, Liu Z, Li X, Zhou SW, Gao YJ. Construction of thrombus-targeted microbubbles carrying tissue plasminogen activator and their in vitro thrombolysis efficacy: a primary research. J Thromb Thrombolysis 2010; 30(1): 29–35
https://doi.org/10.1007/s11239-010-0450-z
pmid: 20155435
|
129 |
Hua X, Zhou L, Liu P, He Y, Tan K, Chen Q, Gao Y, Gao Y.In vivo thrombolysis with targeted microbubbles loading tissue plasminogen activator in a rabbit femoral artery thrombus model. J Thromb Thrombolysis 2014; 38(1): 57–64
https://doi.org/10.1007/s11239-014-1071-8
pmid: 24671732
|
130 |
Absar S, Nahar K, Kwon YM, Ahsan F. Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy. Pharm Res 2013; 30(6): 1663–1676
https://doi.org/10.1007/s11095-013-1011-x
pmid: 23468049
|
131 |
Absar S, Kwon YM, Ahsan F. Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis. J Control Release 2014; 177: 42–50
https://doi.org/10.1016/j.jconrel.2013.12.036
pmid: 24417965
|
132 |
Jun CD, Shimaoka M, Carman CV, Takagi J, Springer TA. Dimerization and the effectiveness of ICAM-1 in mediating LFA-1-dependent adhesion. Proc Natl Acad Sci USA 2001; 98(12): 6830–6835
https://doi.org/10.1073/pnas.121186998
pmid: 11391003
|
133 |
Decuzzi P, Ferrari M. The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials 2006; 27(30): 5307–5314
https://doi.org/10.1016/j.biomaterials.2006.05.024
pmid: 16797691
|
134 |
Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013; 13(3): 159–175
https://doi.org/10.1038/nri3399
pmid: 23435331
|
135 |
Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013; 339(6116): 161–166
https://doi.org/10.1126/science.1230719
pmid: 23307733
|
136 |
Demos SM, Dagar S, Klegerman M, Nagaraj A, McPherson DD, Onyuksel H. In vitro targeting of acoustically reflective immunoliposomes to fibrin under various flow conditions. J Drug Target 1998; 5(6): 507–518
https://doi.org/10.3109/10611869808997876
pmid: 9783681
|
137 |
Klegerman ME, Huang S, Parikh D, Martinez J, Demos SM, Onyuksel HA, McPherson DD. Lipid contribution to the affinity of antigen association with specific antibodies conjugated to liposomes. Biochim Biophys Acta 2007; 1768(7): 1703–1716
https://doi.org/10.1016/j.bbamem.2007.04.007
pmid: 17509522
|
138 |
Zimarino M, D’Andreamatteo M, Waksman R, Epstein SE, De Caterina R. The dynamics of the coronary collateral circulation. Nat Rev Cardiol 2014; 11(4): 191–197
https://doi.org/10.1038/nrcardio.2013.207
pmid: 24395049
|
139 |
Bode C, Meinhardt G, Runge MS, Freitag M, Nordt T, Arens M, Newell JB, Kübler W, Haber E. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation 1991; 84(2): 805–813
https://doi.org/10.1161/01.CIR.84.2.805
pmid: 1860223
|
140 |
Xie F, Lof J, Matsunaga T, Zutshi R, Porter TR. Diagnostic ultrasound combined with glycoprotein IIb/IIIa-targeted microbubbles improves microvascular recovery after acute coronary thrombotic occlusions. Circulation 2009; 119(10): 1378–1385
https://doi.org/10.1161/CIRCULATIONAHA.108.825067
pmid: 19255341
|
141 |
Korin N, Kanapathipillai M, Matthews BD, Crescente M, Brill A, Mammoto T, Ghosh K, Jurek S, Bencherif SA, Bhatta D, Coskun AU, Feldman CL, Wagner DD, Ingber DE. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science 2012; 337(6095): 738–742
https://doi.org/10.1126/science.1217815
pmid: 22767894
|
142 |
Kempe M, Kempe H, Snowball I, Wallén R, Arza CR, Götberg M, Olsson T. The use of magnetite nanoparticles for implant-assisted magnetic drug targeting in thrombolytic therapy. Biomaterials 2010; 31(36): 9499–9510
https://doi.org/10.1016/j.biomaterials.2010.07.107
pmid: 20732712
|
143 |
Chen JP, Yang PC, Ma YH, Tu SJ, Lu YJ. Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle. Int J Nanomed 2012; 7:5137–5149
|
144 |
Yang HW, Hua MY, Lin KJ, Wey SP, Tsai RY, Wu SY, Lu YC, Liu HL, Wu T, Ma YH. Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis. Int J Nanomed 2012; 7:5159–5173
|
145 |
Torno MD, Kaminski MD, Xie Y, Meyers RE, Mertz CJ, Liu X, O’Brien WD Jr, Rosengart AJ. Improvement of in vitro thrombolysis employing magnetically-guided microspheres. Thromb Res 2008; 121(6): 799–811
https://doi.org/10.1016/j.thromres.2007.08.017
pmid: 17942144
|
146 |
Wang M, Zhang J, Yuan Z, Yang W, Wu Q, Gu H. Targeted thrombolysis by using of magnetic mesoporous silica nanoparticles. J Biomed Nanotechnol 2012; 8(4): 624–632
https://doi.org/10.1166/jbn.2012.1416
pmid: 22852472
|
147 |
Vaidya B, Agrawal GP, Vyas SP. Functionalized carriers for the improved delivery of plasminogen activators. Int J Pharm 2012; 424(1-2): 1–11
https://doi.org/10.1016/j.ijpharm.2011.12.032
pmid: 22222184
|
148 |
Dewerchin M, Lijnen HR, Stassen JM, De Cock F, Quertermous T, Ginsberg MH, Plow EF, Collen D. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo. Blood 1991; 78(4): 1005–1018
pmid: 1831057
|
149 |
Asahi M, Rammohan R, Sumii T, Wang X, Pauw RJ, Weissig V, Torchilin VP, Lo EH. Antiactin-targeted immunoliposomes ameliorate tissue plasminogen activator-induced hemorrhage after focal embolic stroke. J Cereb Blood Flow Metab 2003; 23(8): 895–899
https://doi.org/10.1097/01.WCB.0000072570.46552.DF
pmid: 12902833
|
150 |
Underwood MJ, Pringle S, de Bono DP. Reduction of thrombus formation in vivo using a thrombolytic agent targeted at damaged endothelial cells. Br J Surg 1992; 79(9): 915–917
https://doi.org/10.1002/bjs.1800790920
pmid: 1422755
|
151 |
Maksimenko AV, Petrov AD, Tischenko EG, Smirnov MD. Experimentally targeted thrombolytic therapy. Application of modified thrombin conjugated with urokinase. Ann N Y Acad Sci 1995; 750(496–501
|
152 |
Murciano JC, Higazi AA, Cines DB, Muzykantov VR. Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile. J Control Release 2009; 139(3): 190–196
https://doi.org/10.1016/j.jconrel.2009.07.003
pmid: 19616049
|
153 |
Lian Q, Szarka SJ, Ng KK, Wong SL. Engineering of a staphylokinase-based fibrinolytic agent with antithrombotic activity and targeting capability toward thrombin-rich fibrin and plasma clots. J Biol Chem 2003; 278(29): 26677–26686
https://doi.org/10.1074/jbc.M303241200
pmid: 12736246
|
154 |
Muzykantov VR, Barnathan ES, Atochina EN, Kuo A, Danilov SM, Fisher AB. Targeting of antibody-conjugated plasminogen activators to the pulmonary vasculature. J Pharmacol Exp Ther 1996; 279(2): 1026–1034
pmid: 8930213
|
155 |
Murciano JC, Muro S, Koniaris L, Christofidou-Solomidou M, Harshaw DW, Albelda SM, Granger DN, Cines DB, Muzykantov VR. ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood 2003; 101(10): 3977–3984
https://doi.org/10.1182/blood-2002-09-2853
pmid: 12531816
|
156 |
Hagemeyer CE, Tomic I, Jaminet P, Weirich U, Bassler N, Schwarz M, Runge MS, Bode C, Peter K. Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide. Thromb Haemost 2004; 92(1): 47–53
pmid: 15213844
|
157 |
Line BR, Weber PB, Lukasiewicz R, Dansereau RN. Reduction of background activity through radiolabeling of antifibrin Fab' with 99mTc-dextran. J Nucl Med 2000; 41(7): 1264–1270
pmid: 10914920
|
158 |
Marsh JN, Senpan A, Hu G, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine (Lond) 2007; 2(4): 533–543
https://doi.org/10.2217/17435889.2.4.533
pmid: 17716136
|
159 |
Yurko Y, Maximov V, Andreozzi E, Thompson GL, Vertegel AA. Design of biomedical nanodevices for dissolution of blood clots. Mater Sci Eng C 2009; 29(3): 737–741
https://doi.org/10.1016/j.msec.2009.01.017
|
160 |
Piras AM, Chiellini F, Fiumi C, Bartoli C, Chiellini E, Fiorentino B, Farina C. A new biocompatible nanoparticle delivery system for the release of fibrinolytic drugs. Int J Pharm 2008; 357(1-2): 260–271
https://doi.org/10.1016/j.ijpharm.2008.01.035
pmid: 18313868
|
161 |
Torchilin VP, Maksimenko AV, Tischenko EG, Ignashenkova GV, Ermolin GA. Immobilized thrombolytic enzymes possessing increased affinity toward substrate. Ann N Y Acad Sci 1984; 434:289–291
|
162 |
Runge MS, Bode C, Matsueda GR, Haber E. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo. Proc Natl Acad Sci USA 1987; 84(21): 7659–7662
https://doi.org/10.1073/pnas.84.21.7659
pmid: 3118374
|
163 |
Runge MS, Bode C, Matsueda GR, Haber E. Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro. Biochemistry 1988; 27(4): 1153–1157
https://doi.org/10.1021/bi00404a012
pmid: 3130094
|
164 |
Bode C, Matsueda GR, Hui KY, Haber E. Antibody-directed urokinase: a specific fibrinolytic agent. Science 1985; 229(4715): 765–767
https://doi.org/10.1126/science.4023710
pmid: 4023710
|
165 |
Bode C, Runge MS, Newell JB, Matsueda GR, Haber E. Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin. J Biol Chem 1987; 262(22): 10819–10823
pmid: 3611093
|
166 |
Dewerchin M, Lijnen HR, Van Hoef B, De Cock F, Collen D. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin. Eur J Biochem 1989; 185(1): 141–149
https://doi.org/10.1111/j.1432-1033.1989.tb15095.x
pmid: 2530085
|
167 |
Collen D, Dewerchin M, Rapold HJ, Lijnen HR, Stassen JM. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model. Circulation 1990; 82(5): 1744–1753
https://doi.org/10.1161/01.CIR.82.5.1744
pmid: 2121385
|
168 |
Collen D, Dewerchin M, Stassen JM, Kieckens L, Lijnen HR. Thrombolytic and pharmacokinetic properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin. Fibrinolysis 1989; 3(4): 197–202
https://doi.org/10.1016/0268-9499(89)90046-5
|
169 |
Liang JF, Li YT, Song H, Park YJ, Naik SS, Yang VC. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs. J Control Release 2002; 78(1-3): 67–79
https://doi.org/10.1016/S0168-3659(01)00484-9
pmid: 11772450
|
170 |
Yang VC, Naik SS, Song H, Dombkowski AA, Crippen G, Liang JF. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis. J Control Release 2005; 110(1): 164–176
https://doi.org/10.1016/j.jconrel.2005.09.027
pmid: 16260060
|
171 |
Bode C, Runge MS, Schönermark S, Eberle T, Newell JB, Kübler W, Haber E. Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator. Circulation 1990; 81(6): 1974–1980
https://doi.org/10.1161/01.CIR.81.6.1974
pmid: 2111744
|
172 |
Bode C, Runge MS, Newell JB, Matsueda GR, Haber E. Thrombolysis by a fibrin-specific antibody Fab'-urokinase conjugate. J Mol Cell Cardiol 1987; 19(4): 335–341
https://doi.org/10.1016/S0022-2828(87)80578-3
pmid: 3612817
|
173 |
Dewerchin M, Lijnen HR, Collen D. Characterisation of a chemical conjugate between a low molecular weight form of recombinant single chain urokinase-type plasminogen activator (comprising leu-144 through leu-411) and F(ab')2-fragments of a fibrin D-dimer-specific monoclonal antibody. Fibrinolysis 1990; 4(1): 11–18
https://doi.org/10.1016/S0268-9499(05)80035-9
|
174 |
Lijnen HR, Dewerchin M, De Cock F, Collen D. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator. Thromb Res 1990; 57(3): 333–342
https://doi.org/10.1016/0049-3848(90)90249-C
pmid: 2107593
|
175 |
Runge MS, Harker LA, Bode C, Ruef J, Kelly AB, Marzec UM, Allen E, Caban R, Shaw SY, Haber E, Hanson SR. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation 1996; 94(6): 1412–1422
https://doi.org/10.1161/01.CIR.94.6.1412
pmid: 8823001
|
176 |
Holvoet P, Laroche Y, Lijnen HR, Van Cauwenberge R, Demarsin E, Brouwers E, Matthyssens G, Collen D. Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase. J Biol Chem 1991; 266(29): 19717–19724
pmid: 1918077
|
177 |
Shaw GJ, Meunier JM, Huang SL, Lindsell CJ, McPherson DD, Holland CK. Ultrasound-enhanced thrombolysis with tPA-loaded echogenic liposomes. Thromb Res 2009; 124(3): 306–310
https://doi.org/10.1016/j.thromres.2009.01.008
pmid: 19217651
|
178 |
Tiukinhoy-Laing SD, Huang S, Klegerman M, Holland CK, McPherson DD. Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes. Thromb Res 2007; 119(6): 777–784
https://doi.org/10.1016/j.thromres.2006.06.009
pmid: 16887172
|
179 |
Laing ST, Moody M, Smulevitz B, Kim H, Kee P, Huang S, Holland CK, McPherson DD. Ultrasound-enhanced thrombolytic effect of tissue plasminogen activator-loaded echogenic liposomes in an in vivo rabbit aorta thrombus model—brief report. Arterioscler Thromb Vasc Biol 2011; 31(6): 1357–1359
https://doi.org/10.1161/ATVBAHA.111.225938
pmid: 21441137
|
180 |
AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; 331(8585): 545–549 PMID:2894490
|
181 |
Robbins KC, Tanaka Y. Covalent molecular weight approximately 92 000 hybrid plasminogen activator derived from human plasmin amino-terminal and urokinase carboxyl-terminal domains. Biochemistry 1986; 25(12): 3603–3611
https://doi.org/10.1021/bi00360a019
pmid: 2941075
|
182 |
Robbins KC, Boreisha IG. A covalent molecular weight approximately 92,000 hybrid plasminogen activator derived from human plasmin fibrin-binding and tissue plasminogen activator catalytic domains. Biochemistry 1987; 26(15): 4661–4667
https://doi.org/10.1021/bi00389a011
pmid: 3117104
|
183 |
Maksimenko AV, Torchilin VP. Water-soluble urokinase derivatives with increased affinity to the fibrin clot. Thromb Res 1985; 38(3): 289–295
https://doi.org/10.1016/0049-3848(85)90157-4
pmid: 4024044
|
184 |
Maksimenko AV, Samarenko MB, Petrov AD, Tischenko EG, Ruda M, Torchilin VP. Fibrinogen-immobilized urokinase demonstrates increased thrombolytic activity in animal experiments. Ann N Y Acad Sci 1990; 613:479–482
|
185 |
Klegerman M, Parikh D, Tiukinhoy-Laing S, McPherson D. Ability of human tissue plasminogen activator to act as a targeting agent in tPA-loaded echogenic liposomes. AAPS J 2006; 8(S2):Abstr. T2111
|
186 |
Moody M, Laing ST, Huang S, Kim H, Smulevitz B, Zou Y, McPherson DD, Klegerman ME. Doppler ultrasound enhances the thrombolytic activity of tissue-plasminogen activator-loaded echogenic liposomes. Circulation 2007; 116: II-646
|
187 |
Smith DA, Vaidya SS, Kopechek JA, Huang SL, Klegerman ME, McPherson DD, Holland CK. Ultrasound-triggered release of recombinant tissue-type plasminogen activator from echogenic liposomes. Ultrasound Med Biol 2010; 36(1): 145–157
https://doi.org/10.1016/j.ultrasmedbio.2009.08.009
pmid: 19900755
|
188 |
Laing ST, Moody MR, Kim H, Smulevitz B, Huang SL, Holland CK, McPherson DD, Klegerman ME. Thrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model. Thromb Res 2012; 130(4): 629–635
https://doi.org/10.1016/j.thromres.2011.11.010
pmid: 22133272
|
189 |
Heeremans JL, Kraaijenga JJ, Los P, Kluft C, Crommelin DJ. Development of a procedure for coupling the homing device glu-plasminogen to liposomes. Biochim Biophys Acta 1992; 1117(3): 258–264
https://doi.org/10.1016/0304-4165(92)90022-M
pmid: 1384709
|
190 |
Gidlöf AC, Ocaya P, Krivospitskaya O, Sirsjö A. Vitamin A: a drug for prevention of restenosis/reocclusion after percutaneous coronary intervention? Clin Sci (Lond) 2008; 114(1): 19–25
https://doi.org/10.1042/CS20070090
pmid: 18047466
|
191 |
Glagov S. Intimal hyperplasia, vascular modeling, and the restenosis problem. Circulation 1994; 89(6): 2888–2891
https://doi.org/10.1161/01.CIR.89.6.2888
pmid: 8205705
|
192 |
Labinaz M, Pels K, Hoffert C, Aggarwal S, O’Brien ER. Time course and importance of neoadventitial formation in arterial remodeling following balloon angioplasty of porcine coronary arteries. Cardiovasc Res 1999; 41(1): 255–266
https://doi.org/10.1016/S0008-6363(98)00203-X
pmid: 10325973
|
193 |
Molero L, López-Farré A, Mateos-Cáceres PJ, Fernández-Sánchez R, Luisa Maestro M, Silva J, Rodríguez E, Macaya C. Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery. Br J Pharmacol 2005; 146(3): 419–424
https://doi.org/10.1038/sj.bjp.0706340
pmid: 16041401
|
194 |
Pickering JG, Weir L, Jekanowski J, Kearney MA, Isner JM. Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. J Clin Invest 1993; 91(4): 1469–1480
https://doi.org/10.1172/JCI116352
pmid: 8097207
|
195 |
Vandelli L, Marietta M, Gambini M, Cavazzuti M, Trenti T, Cenci MA, Casoni F, Bigliardi G, Pentore R, Nichelli P, Zini A. Fibrinogen decrease after intravenous thrombolysis in ischemic stroke patients is a risk factor for intracerebral hemorrhage. J Stroke Cerebrovasc Dis 2015; 24(2): 394–400
https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.09.005
pmid: 25497721
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|